Heart Failure

The study found that more than a third of patients who were obese said they did not receive advice on physical activity or nutrition in order to lose weight, and nearly 1 in 5 said they were not even told they were overweight.

We do not yet know the exact mechanism of action of sodium glucose co-transporter-2 (SGLT2) inhibitors in heart failure (HF), but there are many exciting pssibilities, stated Clyde W. Yancy, MD, MSc, of Northwestern University’s Feinberg School of Medicine.

Patients should continue to be monitored while on treatment with SGLT2 inhibitors if they are being treated for comorbid type 2 diabetes and heart failure, emphasized Mikhail N. Kosiborod, MD, cardiologist, vice president of Research at Saint Luke's Health System.

When the sympathetic nervous system is unregulated, it can lead to high blood pressure and elevated heart rate.

Research from ESC Heart Failure shows a slower standardized gait speed in older adults with heart failure.

A meta-analysis from ESC Heart Failure shows the effects of home telemonitoring in patients with decompensated heart failure.

Statin use benefited individuals with heart failure by lowering their cancer-related risks, both of developing any cancer at all and of dying from the comorbid condition.

Research that will be presented at Heart Failure 2021 shows patients with heart failure may have a greater incidence of several types of cancer and that this chance is even higher in women vs men.

Updates reflect the increased intersection among diabetes, cardiovascular, and kidney disease care among certain drug classes, especially sodium glucose co-transporter 2 (SGLT2) inhibitors.

When comparing atherosclerotic cardiovascular disease (ASCVD) with cancer, patients with both diseases appeared to have the greatest risk of experiencing financial toxicity.

The latest happenings in the heart failure space from across MJH Life Sciences™.

Out-of-pocket (OOP) spending for patients with heart failure with reduced ejection fraction rose in the event of a worsening heart failure event across the 4 phases of Medicare Part D coverage.

Patients with obstructive hypertrophic cardiomyopathy (HCM) use significant health care resources, and mavacamten can help to reduce their symptoms and improve their function, noted Jay Edelberg, MD, PhD, head of Heart Failure and Cardiomyopathy Development at Bristol Myers Squibb.

Progressive rehabilitation produced superior results among patients randomized to a 36-session program during or following hospitalization for acute decompensated heart failure vs those randomized to usual care.

Barriers to authorship and adequate representation of women in heart failure–focused clinical trials need to be addressed, noted Mariana Garcia, MD, cardiology fellow in the Academic Clinical Investigator Pathway at Emory University and member of T32, Multidisciplinary Research Training to Reduce Inequalities in Cardiovascular Health (METRIC).

Data from the DAPA-HF trial and published literature show intermediate-level cost-effectiveness of dapagliflozin use among patients with heart failure with reduced ejection fraction (HFrEF).

The increase in hospitalization risk seen with Vascepa was small vs the survival gains seen from decreased rates of heart attack, stroke, and revascularization, noted Deepak L. Bhatt, MD, MPH, Brigham and Women’s Hospital Heart & Vascular Center.

Mount Sinai research released today shows a possible link between excess pericardial fat and greater risk of heart failure, with implications for early intervention and prevention of heart disease.

The latest coverage in the heart failure space from across MJH Life Sciences™.

We want to use artificial intelligence (AI) to promote the best-case scenario in patient care, emphasized James Januzzi, MD, staff cardiologist at Massachusetts General Hospital.

Rates of acute heart failure (AHF) have recently been rapidly increasing among elderly and super-elderly patients in Japan, and this study investigated rates of all-cause death and mode of death among this patient population.

These 4 studies were pegged as “ones to watch” during the American College of Cardiology (ACC) annual briefing on results for consumers. They will be presented in the opening session of late-breaking clinical trial results on day 1 of ACC.21.

Both studies were featured during the American College of Cardiology's annual briefing on results for consumers. They will be presented during the 70th Scientific Session, which is set for May 15-17, 2021.

Compared with nonsmokers who did not have recent exposure to secondhand smoke, a 35% greater chance for heart failure was seen among those with recent exposure to the toxic fumes.

Right ventricular systolic function evaluated through VO2 max is a more accurate measure of functional capacity of persons with heart failure compared with left ventricular systolic function.

Findings from a new study out of Mount Sinai in New York show a small but rare chance of developing new-onset heart failure following hospitalization for COVID-19.

A new approach to identifying and defining heart failure among patients with chronic obstructive pulmonary disease (COPD) involves combining information gleaned from reviewing their electronic medical records and examination charts.

Overweight and obese adults, whose body mass index trended upward in a recent UK study, had higher risk of heart failure, all-cause mortality, and cardiovascular disease–related mortality.

This recent study out of Japan compared the use of renin-angiotensin system inhibitors and β-blockers among patients with heart failure, both those who had physical limitations and those who did not.

Elevated levels of 2 inflammatory biomarkers may indicate a greater heart failure hospitalization risk for patients who have diagnosed atrial fibrillation.